Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -69.44% is 38% below its 4-year average of -50.20%, near the low end of its 4-year range (-80.28%–-30.82%).
43.56% below its 12-month average of -48.37%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -17.43%.
RETURN ON ASSETS (ROA)
-69.44%
RETURN ON ASSETS (ROA) AVG TTM
-48.37%
RETURN ON ASSETS (ROA) AVG 3Y
-55.05%
RETURN ON ASSETS (ROA) AVG 5Y
N/A
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-43.56%
CURRENT VS 3Y AVG
-26.15%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-115.38%
vs the sector median at left
Kyverna Therapeutics, Inc.
Market Cap
$378.15M
Return on Assets (ROA)
-69.44%
TTM Avg
-48.37%
3Y Avg
-55.05%
5Y Avg
N/A
Market Cap
$378.03M
Return on Assets (ROA)
-41.58%
TTM Avg
-23.89%
3Y Avg
-13.16%
5Y Avg
-19.94%
Market Cap
$380.94M
Return on Assets (ROA)
-40.18%
TTM Avg
-44.72%
3Y Avg
-159.61%
5Y Avg
-126.49%
Market Cap
$375.21M
Return on Assets (ROA)
-24.06%
TTM Avg
-44.34%
3Y Avg
-68.40%
5Y Avg
-50.78%
Market Cap
$383.02M
Return on Assets (ROA)
-7.07%
TTM Avg
-12.47%
3Y Avg
-11.40%
5Y Avg
-8.86%
Market Cap
$380.36M
Return on Assets (ROA)
-29.57%
TTM Avg
-40.44%
3Y Avg
-13.88%
5Y Avg
-8.39%
Market Cap
$365.67M
Return on Assets (ROA)
-115.75%
TTM Avg
-127.38%
3Y Avg
-59.19%
5Y Avg
-98.90%
Market Cap
$393.42M
Return on Assets (ROA)
-50.81%
TTM Avg
-45.77%
3Y Avg
-42.77%
5Y Avg
-29.22%
Market Cap
$358.93M
Return on Assets (ROA)
6.92%
TTM Avg
7.42%
3Y Avg
10.30%
5Y Avg
25.30%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | $378.15M | -69.44% | -48.37% | -55.05% | N/A |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $378.03M | -41.58% | -23.89% | -13.16% | -19.94% |
| Zura Bio Limited (ZURA)vs › | $380.94M | -40.18% | -44.72% | -159.61% | -126.49% |
| Canopy Growth Corporation (CGC)vs › | $375.21M | -24.06% | -44.34% | -68.40% | -50.78% |
| Orthofix Medical Inc. (OFIX)vs › | $383.02M | -7.07% | -12.47% | -11.40% | -8.86% |
| YD Bio Limited Ordinary Shares (YDES)vs › | $380.36M | -29.57% | -40.44% | -13.88% | -8.39% |
| Opus Genetics, Inc. (IRD)vs › | $365.67M | -115.75% | -127.38% | -59.19% | -98.90% |
| REGENXBIO Inc. (RGNX)vs › | $393.42M | -50.81% | -45.77% | -42.77% | -29.22% |
| Embecta Corp. (EMBC)vs › | $358.93M | 6.92% | 7.42% | 10.30% | 25.30% |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $357.37M | -21.30% | -29.99% | -30.23% | -24.37% |
ROA
-69.4%
ROE
-92.2%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -54.90% |
| 2024-12-31 | -41.84% |
| 2023-12-31 | -80.28% |
| 2022-12-31 | -43.17% |
| 2021-12-31 | -30.82% |
